Scott Megaffin, CEO of Adastra Pharmaceuticals, Inc., a company focused on the treatment of cancers with high unmet needs (such as high-grade gliomas), discusses positive top-line data from their Phase 1b clinical trial conducted by the National Cancer Institute evaluating zotiraciclib (ZTR/TG02) in combination with temozolomide (TMZ) in patients with recurrent high-grade gliomas, which have a near-100% mortality rate and very limited therapeutic options. He also talks about Adastra’s plans for the future development of ZTR.
Scott Megaffin, Chief Executive Officer at Adastra Pharmaceuticals Inc. Mr. Megaffin has more than 30 years of related experience in the pharmaceutical industry. Scott plans and directs all aspects of Adastra operational objectives, policies and initiatives. He is responsible for the development of the functional business strategy of Adastra, including investor relations and communication of the corporate vision and supporting values. Prior to joining Adastra, Mr. Megaffin served as President of Churchill Pharmaceuticals LLC, sold to Sun Pharma in 2018. Scott has held numerous global strategic and operational positions of increasing responsibility including Senior Vice President of Commercial Development for Onconova Therapeutics, Inc., also Cephalon, Adolor, Yamounchi and Bristol-Myers Squibb. He has led six global drug approvals and development programs, within a variety of therapeutic categories including oncology, hematology, virology, critical care, anti-infectives, pain and inflammation. Scott received a B.S. in Biology from Pittsburg State University.